RankingsPricing
  1. US-listed companies
  2. REGENERON PHARMACEUTICALS, INC.
  3. Financials
  4. Net income

REGENERON PHARMACEUTICALS, INC.REGN

Market cap
$81.6B
P/E ratio
SummaryFinancials
Period EndNet income (Million USD)YoY (%)
Dec 31, 20244,413+11.61%
Dec 31, 20233,954-8.87%
Dec 31, 20224,338-46.28%
Dec 31, 20218,075+129.86%
Dec 31, 20203,513+66.05%
Dec 31, 20192,116-13.44%
Dec 31, 20182,444+103.95%
Dec 31, 20171,199+33.83%
Dec 31, 2016896+40.79%
Dec 31, 2015636+82.74%
Dec 31, 2014348-17.98%
Dec 31, 2013424-43.44%
Dec 31, 2012750-438.32%
Dec 31, 2011-222+112.28%
Dec 31, 2010-104

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)